Top Banner
ASTHMA
65
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Asthma

ASTHMA

Page 2: Asthma

DEFINITIONChronic inflammatory disorder of the airways

Widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment

Bronchial hyperresponsiveness to a variety of stimuli

Page 3: Asthma

affects 300 million people world-widesocio-economic impact is enormous, poor control leads to days lost from school or work, unscheduled health-care visits and hospital admissions

Page 4: Asthma

Adult Asthma Facts14.5 million workdays lost due to asthma, a 2.3 fold increase from the early 80s to the mid 90sAdults accounted for over 1.3 million ED visits and 288,000 hospitalizations due to asthmaOne third of asthma related deaths occur in patients 35-44 years oldOver 50% of asthma related deaths occur in patients 65 years and older

Morb Mortal Wkly Rep. 2002 March 29; 51:1-13.

Page 5: Asthma
Page 6: Asthma

Atopymajor risk factor for asthmagenetically determined production of specific IgE antibodysuffer from other atopic diseases, particularly allergic rhinitis and atopic dermatitis (eczema)most common allergens are - house dust mites, cat and dog fur, cockroaches, grass and tree pollens

Page 7: Asthma

Most Patients with Asthma Have Allergic Rhinitis Approximately 80% of asthmatics have allergic rhinitis

Adapted from The Workshop Expert Panel. Management of Allergic Rhinitis and its Impact on Asthma (ARIA) Pocket Guide. A Pocket Guide for Physicians and Nurses. 2001; Bousquet J and the ARIA Workshop Group J Allergy Clin Immunol 2001;108(5):S147-S334; Sibbald B, Rink E Thorax 1991;46:895-901; Leynaert B et al Am J Respir Crit Care Med 2000;162:1391-1396.

Asthmaalone

Allergic rhinitisalone

Allergicrhinitis

+ asthma

Page 8: Asthma

IgE and Asthma in Adults

Asthma

Serum IgE (IU/mL)

Od

ds

ra

tio

N = 2657

0.32 1 3.2 10 32 100 320 1000 3200

11

2.52.5

55

1010

2020

4040

Burrows B, et al. New Engl J Med. 1989;320:271-277.

Page 9: Asthma

Intrinsic Asthmanegative skin tests to common inhalant allergens and normal serum concentrations of IgElater onset of disease (adult-onset asthma), commonly have concomitant nasal polyps, and may be aspirin-sensitive

Page 10: Asthma

THE HYGIENE HYPOTHESIS

Page 11: Asthma

AIR POLLUTIONsulfur dioxide, ozone, and diesel particulates, may trigger asthma symptomsIndoor air pollution may be more important with exposure to nitrogen oxides from cooking stoves and exposure to passive cigarette smoke

Page 12: Asthma

OCCUPATIONAL EXPOSURE

relatively common and may affect up to 10% of young adultsChemicals such as toluene diisocyanate and trimellitic anhydride, fungal amylase in wheat flour in bakerssuspected when symptoms improve during weekends and holidays

Page 13: Asthma

ALLERGEN SENSITIZATION

Page 14: Asthma
Page 15: Asthma

DENDRITIC CELL WITH AN ALLERGEN

Page 16: Asthma

DENDRITIC CELL CAPTURES THE ALLERGEN AND RUNS WITH IT TO THE LYMPH NODE

Page 17: Asthma

DENDRITIC CELL RELEASES THE

ALLERGEN

Page 18: Asthma

T CELL CAPTURES THE ALLERGEN

Page 19: Asthma

CELL RECRUITMENT

Page 20: Asthma

MUSCLE CELL HYPERTROPHY

Page 21: Asthma

TISSUEDAMAG

E

Page 22: Asthma

MORE TISSUE DAMAGE

Page 23: Asthma

IgE-dependent Release of Inflammatory Mediators

IgEAllergens

FcεRI

Over MinutesLipid mediators: ProstaglandinsLeukotrienes

WheezingBronchoconstriction

Over HoursCytokine production:Specifically IL-4, IL-13

Mucus productionEosinophil recruitment

Immediate ReleaseGranule contents:Histamine, TNF-α, Proteases, Heparin

Sneezing Nasal congestionItchy, runny noseWatery eyes

Page 24: Asthma

Before 10 Minutes After Allergen Challenge

Bronchoconstriction

Page 25: Asthma

Mechanisms of Airway Obstruction

Smooth MuscleContraction

MucusHypersecretion

Loss of ElasticRecoil

? PeribronchialFibrosis

Airway WallEdema

Vascular dilatation

Page 26: Asthma

Airway Inflammation in Asthma

Page 27: Asthma

Acute Fatal Asthma

Impact of Inflammation on Small AirwaysImpact of Inflammation on Small Airways

Normal Chronic Severe Asthma

Page 28: Asthma

CLINICAL FEATURES AND

DIAGNOSIS

Page 29: Asthma

SYMPTOMSRecurrent episodes of:

Shortness of breathWheezingChest tightnessCough, particularly at night and early in the morning

Page 30: Asthma

PATTERN OF SYMPTOMSPerennial, seasonal or both

Continual, episodic or both

Diurnal variations, especially nocturnal and on awakening early in the morning

Page 31: Asthma

PRECIPITATING AND/OR AGGRAVATING FACTORS

Viral respiratory infectionsEnvironmental allergensExerciseOccupational chemicals or allergensIrritantsChanges in weatherEndocrine factorsGERDSinusitis

Page 32: Asthma

PHYSICAL EXAMNormal physical exam - asthma is under controlExpiratory wheezing with normal or decreased air movementAccessory respiratory muscle useOminous sign- no wheezing with decreased air movement

Page 33: Asthma

Cough may be the dominant symptom in some patients, and the lack of wheeze or breathlessness may lead to a delay in reaching the diagnosis of so-called ‘cough-variant asthma

Page 34: Asthma

EVALUATION

CLINICAL HISTORYSPIROMETRYMETHACHOLLINE CHALLENGE TESTALLERGY SKIN TESTS

Page 35: Asthma

Spirometry: A Simple, Basic Measurement

Essential to initial evaluationHelps assess severity of airflow obstructionAids in differential diagnosis

Obstructive versus restrictive airway diseaseReversibility of airflow obstruction

Confirms periodic home PEFR measurements in selected patients

Page 36: Asthma

Spirometry in asthma

reduced FEV1, FEV1/FVC ratio, and PEFImprovement in FEV1>12% with bronchodilator therapy Measurements of PEF twice daily may confirm the diurnal variations in airflow obstruction – more than 20% is considered diagnostic

Page 37: Asthma
Page 38: Asthma
Page 39: Asthma
Page 40: Asthma
Page 41: Asthma

FlowFlow

(l/s)(l/s)

Volume (l)Volume (l)

-2-2

00

-4-4

11

33

22

44

55

21 3 4 5

-6-6

Pre-albuterolPost-albuterolPredicted

Spirometry: Flow-Volume Loops in Asthma

Page 42: Asthma

Bronchoprovocation Challenges

methacholine or histamine challenge calculation of the provocative concentration that reduces FEV1 by 20% (PC20)Measures the increased AHRexercise testing is done to demonstrate the postexercise bronchoconstriction if there is anpredominant history of EIA

Page 43: Asthma

Reasons for Performing Bronchoprovocation Challenges in

Clinical Practice

To quantify the severity of the airway hyperresponsiveness(AHR)Clarify a clinical diagnosis of asthma when a reasonable degree of doubt existsTo determine the presence of bronchial hyperresponsiveness in patients with chronic cough

Page 44: Asthma

ALLERGIC TRIGGERS

Page 45: Asthma

INHALANT ALLERGENS

Animal allergensHouse-dust mites Cockroach allergensIndoor fungi (molds)Outdoor allergens

Page 46: Asthma

ALLERGEN SKIN TESTS

Eugene Braunwald, Atlas of Internal Medicine, 2nd edition

Page 47: Asthma

EVALUATIONCBC with differential ( eosinophilia often seen in asthma, ABPA and CS vasculitis)Total igEspecific IgE to inhaled allergens [radioallergosorbent test(RAST)]CXRCT of the chestABG in status asthmaticus

Page 48: Asthma

Exhaled NO is now being used as a noninvasive test to measure eosinophilic airway inflammationThe typically elevated levels in asthma are reduced by ICS, so this may be a test of compliance with therapy

Page 49: Asthma

ASTHMA CLASSIFICATION AND THERAPY

Page 50: Asthma

Classification of Asthma Intermittent Asthma Persistent Asthma

MILDsx frequency >2/days per week, not dailyFEV1>80%

MODERATEsx frequency dailyFEV1=60-80%

SEVEREsx frequency throughout the dayFEV1<60%

sx frequency less than 2 times / week sx frequency 2 times / week or more

Page 51: Asthma

Goals of Therapy: Asthma Control

■ Minimal or no chronic symptoms day or night■ Minimal or no exacerbations■ No limitations on activities; no school/work

missed■ Maintain (near) normal pulmonary function■ Minimal use of short-acting inhaled beta2-

agonist■ Minimal or no adverse effects from

medications

Page 52: Asthma

Avoidance of aggravating factors

particularly important occupational asthmarelevant to atopic patients where removing or reducing exposure to relevant antigens, e.g. a pet animal, may effect improvement

Page 53: Asthma

House dust mite exposure may be minimised by replacing carpets with floorboards and using mite impermeable beddingMeasures to reduce fungal exposure and eliminate cockroachesMedications known to precipitate or aggravate asthma should be avoided

Page 54: Asthma

Smoking cessation

Page 55: Asthma

BRONCHODILATOR THERAPIES

beta2-adrenergic agonists, anticholinergics, and theophyllineShort-acting beta2-agonists (SABAs) such as albuterol and terbutaline – doa 3-6 hrs Long-acting 2-agonists (LABAs) include salmeterol and formoterola doa >12 hours

Page 56: Asthma

CONTROLLER THERAPIES

Inhaled Corticosteroids - most effective controllers for asthmaSystemic CorticosteroidsAntileukotrienes - montelukast and zafirlukastCromones - Cromolyn sodium and nedocromil sodiumAnti-IgE -Omalizumab

Page 57: Asthma

MANAGEMENT OF CHRONIC ASTHMA

Page 58: Asthma
Page 59: Asthma
Page 60: Asthma
Page 61: Asthma

Asthma in pregnancy

Page 62: Asthma
Page 63: Asthma

ACUTE SEVERE ASTHMA

Page 64: Asthma
Page 65: Asthma